Serotonin 2A receptor agonist binding in the human brain with [11C] Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [18F] altanserin
Serotonin 2A receptor agonist binding in the human brain with [11C] Cimbi-36: Test-retest reproducibility and head-to-head comparison with the antagonist [18F] altanserin
复制标题
DOI：
10.1016/j.neuroimage.2016.02.001
复制
发表时间：
2016-04-15
期刊：
影响因子：
5.7
通讯作者：
Knudsen, Gitte Moos
中科院分区：
文献类型：
--
作者：
Ettrup, Anders;Svarer, Claus;Knudsen, Gitte Moos
前言：[C-11]Cimbi-36是新近开发的5-羟色胺2A(5-HT2A)受体激动剂正电子发射断层扫描(PET)放射配基，已成功应用于人类神经成像。在这里，我们研究了脑[C-11]Cimbi-36 PET的重测变异性，并比较了[C-11]Cimbi-36和5-HT2A受体拮抗剂[F-18]Altanserin。方法：16名健康志愿者(平均年龄23.9+/-6.4岁，男性6例)用高分辨率研究断层扫描PET扫描仪进行了两次扫描。所有受试者在注射[C-11]Cimbi-36后进行扫描；8人接受两次扫描，以确定[C-11]Cimbi-36结合措施的测试-重测变异性；另外8人在注射加持续输注[F-18]Altanserin后进行扫描。[C-11]Cimbi-36和[F-18]Altanserin在脑内分布的区域差异通过区域结合测量的相关性和基于体素的分析来评估。结果：[C-11]Cimbi-36非置换结合势(BPND)的重测变异性一致
Introduction: [C-11] Cimbi-36 is a recently developed serotonin 2A (5-HT2A) receptor agonist positron emission tomography (PET) radioligand that has been successfully applied for human neuroimaging. Here, we investigate the test-retest variability of cerebral [C-11] Cimbi-36 PET and compare [C-11] Cimbi-36 and the 5-HT2A receptor antagonist [F-18] altanserin.Methods: Sixteen healthy volunteers (mean age 23.9 +/- 6.4 years, 6 males) were scanned twice with a high resolution research tomography PET scanner. All subjects were scanned after a bolus of [C-11] Cimbi-36; eight were scanned twice to determine test-retest variability in [C-11] Cimbi-36 binding measures, and another eight were scanned after a bolus plus constant infusion with [F-18] altanserin. Regional differences in the brain distribution of [C-11] Cimbi-36 and [F-18] altanserin were assessed with a correlation of regional binding measures and with voxel-based analysis.Results: Test-retest variability of [C-11] Cimbi-36 non-displaceable binding potential (BPND) was consistently